The safety and efficacy of tyrosine kinase inhibitors and programmed cell death protein- 1 inhibitors combined with HAIC/TACE in the treatment of recurrent unresectable hepatocellular carcinoma

Table 3 Univariate Analysis Associated with Progression-free Survival

Variables	Univariate Analysis
Variables	HR (95% CI)	p-value
Male	1.32(0.53–3.28)	0.556
Age	0.99(0.97–1.01)	0.328
Hepatitis B surface antigen Positive	0.88(0.44–1.78)	0.724
Liver cirrhosis	0.94(0.58–1.52)	0.803
AFP ≥ 400 ng/mL	2.60(1.47–4.61)	0.001
ALT	0.92(0.53–1.59)	0.754
AST	0.94(0.55–1.60)	0.818
GGT	0.75(0.47–1.20)	0.230
ALP	1.07(0.59–1.97)	0.817
PT	1.25(1.02–1.54)	0.036
Number of intrahepatic lesions > 3	1.03(0.63–1.67)	0.911
Maximum diameter of intrahepatic tumor > 5 cm	1.03(0.52–2.03)	0.928
Vascular invasion	1.97(0.47–8.15)	0.352
Extrahepatic metastases	0.56(0.28–1.14)	0.110
Time to recurrence after surgery ≥ 2	0.48(0.25–0.89)	0.021
ALBI grade (1/2/3)	1.20(0.78–1.84)	0.411
ECGO PS (0)	-	-
Child–Pugh (A/B)	1.21(0.38–3.86)	0.748
Pre-operative AFP ≥ 400 ng/mL	0.77(0.46–1.29)	0.321
Microvascular invasion(M0/M1/M2)	1.29(0.97–1.72)	0.080
Tumor differentiation (L/M/H)	0.65(0.39–1.11)	0.113
Satellite nodule	2.00(1.07–3.73)	0.029
HTP vs TTP	0.79(0.40–1.58)	0.510
HTP vs TACE	0.34(0.19–0.60)	0.001
TTP vs TACE	0.40(0.21–0.73)	0.003

AFP alpha-fetoprotein, ALT alanine aminotransferase, AST aspartate aminotransferase, GGT γ-glutamyl transpeptidase, ALP Alkaline phosphatase, PT prothrombin time, ECOG PS Eastern Cooperative Oncology Group performance status, ALBI albumin-bilirubin, Calculated using the following equation: linear predictor = (log10 bilirubin mmol/L × 0.66) + (albumin g/L × − 0.085). The continuous linear predictor was further categorized into three different grades for prognostic stratification purposes: grade 1 (less than − 2.60), grade 2 (between − 2.60 and − 1.39), and grade 3 (above − 1.39), HTP hepatic arterial infusion chemotherapy combined with tyrosine kinase inhibitors and programmed cell death protein- 1 inhibitors, TTP transarterial chemoembolization combined with tyrosine kinase inhibitors and programmed cell death protein- 1 inhibitors, TACE transarterial chemoembolization, HR hazard ratio, CI indicates confidence interval

ISSN: 1471-2407